References

[1] Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol 2014;61:1247–1252.
[2] Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol 2011;23:1206–1212.
[3] Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013;369:1991–2000.
[4] White DL, Tavakoli-Tabasi S, Kanwal F, Ramsey DJ, Hashmi A, Kuzniarek J, et al. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther 2013;38:28–37.
[5] Garcia-Alvarez M, Pineda-Tenor D, Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology 2014;60:1541–1550.
[6] Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2013;19:5917–5924.
[7] Rahman AH, Branch AD. Vitamin D for your patients with chronic hepatitis C? J Hepatol 2013;58:184–189.
[8] Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011;24:43–50.
[9] Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 2012;56:1231–1239.
[10] Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011;54:1570–1579.

Qing Pang
Kai Qu
Jing-Yao Zhang
Chang Liu*
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong, University College of Medicine, Xi'an, China
*Corresponding author. Address: Department of Hepatobiliary Surgery, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, No. 277 West Yan-ta Road, Xi'an 710061, Shaanxi Province, China.
E-mail address: liuchangdoctor@163.com

CrossMark

Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C"

To the Editor:

We thank Pang *et al.* for their interest in our recently published systematic review and meta-analysis involving 2605 patients which found no association between baseline 25-hydroxyvitamin D level and sustained virologic response (SVR) to interferon-based antiviral therapy in chronic hepatitis C infection [1]. They are correct to highlight the influence of ethnicity on both vitamin D status and genetic polymorphisms in key proteins involved in vitamin D synthesis. The studies included in our meta-analysis contained only a small number of participants of Asian [2] or African-American [3] ethnicity, leading us to highlight the study's inability to adjust for ethnicity as one of its limitations.

With regards to the recently published meta-analysis by García-Álvarez *et al.* [4] evaluating vitamin D status and response to hepatitis C therapy, this study differs from ours in that it includes those with HCV-HIV co-infection. Furthermore, we believe this study has significant methodological issues such as the inclusion of three studies involving the same Italian cohort of approximately 200 patients, and the exclusion of five large studies [2,5–8] from Europe and Australia involving 1569 patients that were readily identifiable using the stated search strategy. Our concerns about this study have recently been published [9] and the validity of the study's findings should be viewed with caution.

Our meta-analysis only evaluates the relationship between baseline vitamin D status and SVR. The impact of vitamin D supplementation on outcomes to interferon-based antiviral therapy, although interesting, is a different clinical question that has not been definitively assessed in prospective, randomized controlled trials. We agree that vitamin D has potential anti-viral, anti-inflammatory, anti-fibrotic and immunomodulatory actions relevant to liver disease, which have been highlighted in a number of pre-clinical studies [10]. However high quality prospective clinical research studies are needed to support the hypothesis that vitamin D deficiency may be responsible for the worse outcomes in HCV related liver disease.

Conflict of interest

The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

References

[1] Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol 2014;61:1247–1252.
[2] Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013;58:467–472.
[3] Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr 2012;96:1025–1031.

[4] García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology 2014;60:1541–1550.
[5] Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010;51:1158–1167.
[6] Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887–893.
[7] Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, et al. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012;7:e40159.
[8] Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, et al. Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One 2014;9:e87974.
[9] Kitson MT, Sarrazin C, Toniutto P, Roberts SK. Relationship between vitamin D status and response to HCV therapy. Hepatology 2015. http://dx.doi.org/10.1002/hep.27797.
[10] Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012;57:897–909.

Matthew T. Kitson[1]
Christoph Sarrazin[2]
Pierluigi Toniutto[3]
Stuart Keith Roberts[1,*]
[1]*The Alfred Hospital, Department of Hepatology, Melbourne, Victoria 3004, Australia*
[2]*J.W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt 60590, Germany*
[3]*Internal Medicine, University of Udine, Department of Medical Sciences Clinical & Experimental, Udine, Italy*
*Corresponding author. Address: The Alfred Hospital, Department of Hepatology, Melbourne, Victoria 3004, Australia. Tel.: +61 439633775; fax: +61 390762194.
E-mail address: s.roberts@alfred.org.au

Hepatocyte senescence explains conjugated bilirubinaemia in chronic liver failure

To the Editor:

Conjugated bilirubinaemia in patients with chronic liver disease (CLD) reflects hepatic decompensation and a poor prognosis [1]. The pathophysiology that underlies conjugated bilirubinaemia in hepatic decompensation is poorly understood. There is no demonstrable flaw in processing unconjugated bilirubin and a more likely explanation is altered hepatocyte handling of conjugated bilirubin.

Hepatocyte senescence is present across diverse aetiologies and as many as 80% of hepatocytes show the senescent phenotype in advanced liver disease [2]. Metabolic activity is altered when a cell becomes senescent and one potential consequence is an alteration of conjugated bilirubin transport in senescent hepatocytes, which accumulate in advanced CLD.

Serum bilirubin and hepatocyte telomere length were measured in 70 patients within the spectrum of NAFLD. Mean hepatocyte telomere intensity, a surrogate marker of telomere length, was measured using quantitative fluorescent *in-situ* hybridization, as described [3]. There was an inverse relationship between serum bilirubin and hepatocyte telomere length ($p = 0.04$, Fig. 1). Thus, accelerated hepatocyte ageing is associated with jaundice.

Liver sections from five of those patients were double-stained using unconjugated mouse monoclonal anti-p21 (Dako; concentration 1:100, heat-induced EDTA-based antigen retrieval, 20 min) and unconjugated mouse monoclonal anti-MRP2 (Merck Millipore; concentration 1:20, heat-induced citrate-based antigen retrieval, 20 min). MRP2 was negative in p21-positive (senescent) hepatocytes and was only detected in p21-negative hepatocytes (Fig. 1). Reliable immunohistochemical staining could not be achieved with available MRP3 antibodies.

An *in vitro* model was used to examine gene expression of MRP2 and MRP3 in senescent hepatocytes by real-time PCR. Cellular senescence was induced in HepG2 cells by incubation with 0.5 mM H_2O_2 in culture medium for 60 minutes, as described [4]. Expression of MRP2 was downregulated in senescent HepG2 cells; in contrast, expression of MRP3 was upregulated (Fig. 1).

Hepatocytes are polarised cells; MRP2 is restricted to the canalicular (apical) membrane, whereas MRP3 is found only in the sinusoidal (basolateral) membrane [5]. Both MRP2 and MRP3 are unidirectional efflux pumps, which transport conjugated bilirubin into the canalicular space (bile) or the sinusoid (blood), respectively [5]. Reduced MRP2 expression in senescent hepatocytes *in vitro* and an absence of MRP2 protein in p21-positive (senescent) hepatocytes suggest reduced conjugated bilirubin transport into the biliary canaliculi. Increased MRP3 expression in senescent hepatocytes may be compensatory, increasing transport of conjugated bilirubin into the hepatic sinusoid (Fig. 1). It is, however, not clear why changes in MRP2 and MRP3 accompany hepatocyte senescence.